FluGen Inc
FluGen, Inc. is a vaccine development company focused on creating more effective influenza and respiratory disease vaccines. Their flagship product, the M2SR vaccine platform, aims to revolutionize flu prevention with a vaccine that offers consistent efficacy, broad immune response, and protection against virus drift. They are also exploring applications for COVID-19 and other respiratory diseases, with a mission to develop vaccines that are more effective, durable, and easier to distribute globally.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Single-replication intranasal influenza vaccine candidate (replication-restricted live-virus platform)
An investigational intranasal vaccine based on a replication-restricted influenza virus designed to induce mucosal, humoral and cellular immunity with cross-reactive protection against drifted strains; intended as a platform for combination respiratory vaccines.
Single-replication intranasal influenza vaccine candidate (replication-restricted live-virus platform)
An investigational intranasal vaccine based on a replication-restricted influenza virus designed to induce mucosal, humoral and cellular immunity with cross-reactive protection against drifted strains; intended as a platform for combination respiratory vaccines.
Services
Design and conduct of early-stage clinical studies including Phase 1/1b/2 trials, randomized placebo-controlled studies, dose-escalation and pediatric age de‑escalation protocols, and controlled human challenge studies.
In‑house and collaborative animal challenge studies and immunogenicity assessments in small animal models to evaluate sterilizing immunity, cross-lineage protection and translational endpoints.
Collaborative R&D projects with formulation specialists to develop stable, distribution-ready vaccine formulations suitable for intranasal and other delivery formats.
R&D collaborations to develop viral vector-based platforms capable of delivering multiple antigens for combined protection against different respiratory pathogens.
Process development, scale-up and transfer support for mammalian cell–based vaccine and biologics production, including operations, capital project planning and manufacturing oversight.
Support for quality management systems, manufacturing compliance and regulatory readiness for vaccine production and clinical supply manufacturing.
Design and conduct of early-stage clinical studies including Phase 1/1b/2 trials, randomized placebo-controlled studies, dose-escalation and pediatric age de‑escalation protocols, and controlled human challenge studies.
In‑house and collaborative animal challenge studies and immunogenicity assessments in small animal models to evaluate sterilizing immunity, cross-lineage protection and translational endpoints.
Collaborative R&D projects with formulation specialists to develop stable, distribution-ready vaccine formulations suitable for intranasal and other delivery formats.
R&D collaborations to develop viral vector-based platforms capable of delivering multiple antigens for combined protection against different respiratory pathogens.
Process development, scale-up and transfer support for mammalian cell–based vaccine and biologics production, including operations, capital project planning and manufacturing oversight.
Support for quality management systems, manufacturing compliance and regulatory readiness for vaccine production and clinical supply manufacturing.
Expertise Areas
- Replication-restricted live-virus vaccine development
- Intranasal and mucosal vaccine strategies
- Clinical trial management including pediatric de‑escalation and human challenge studies
- Preclinical infectious disease models and challenge studies
Key Technologies
- Single-replication live-virus constructs
- Intranasal (mucosal) vaccine delivery
- Viral vector insertion of heterologous antigens
- Mammalian cell culture bioproduction and scale-up
News & Updates
FluGen Inc. announced that C. Boyd Clarke has joined as Executive Chairman, bringing extensive vaccine industry experience to the company.
FluGen announced the enrollment completion of a clinical trial evaluating the safety and immune response of their M2SR flu vaccine in children aged 6 months to 17 years.
FluGen plans to conduct a new clinical trial in Europe to test their universal flu vaccine candidate, supported by NIH funding.
UW-Madison virologist Yoshihiro Kawaoka, co-founder of FluGen, was featured in the news for his research on bird flu viruses responsible for deaths in China.
FluGen’s M2SR vaccine platform is being developed as a dual-protection vaccine against both influenza and COVID-19, aiming to address the limitations of current vaccines.
Announcement of leadership change with Boyd Clarke joining as Executive Chairman to help develop FluGen's flu vaccine.
FluGen Inc. announced that C. Boyd Clarke has joined as Executive Chairman, bringing extensive vaccine industry experience to the company.
FluGen announced the enrollment completion of a clinical trial evaluating the safety and immune response of their M2SR flu vaccine in children aged 6 months to 17 years.
FluGen plans to conduct a new clinical trial in Europe to test their universal flu vaccine candidate, supported by NIH funding.
UW-Madison virologist Yoshihiro Kawaoka, co-founder of FluGen, was featured in the news for his research on bird flu viruses responsible for deaths in China.
FluGen’s M2SR vaccine platform is being developed as a dual-protection vaccine against both influenza and COVID-19, aiming to address the limitations of current vaccines.
Announcement of leadership change with Boyd Clarke joining as Executive Chairman to help develop FluGen's flu vaccine.